Related Experiment Video

Updated: Aug 16, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

BCL-2: found bound and drugged!

Anthony Letai1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 530 B, 44 Binney Street, Boston, MA 02115, USA. anthony_letai@dfci.harvard.edu

Trends in Molecular Medicine
|September 10, 2005
PubMed

Insights

Researchers developed a small-molecule antagonist targeting the BCL-2 protein, which inhibits apoptosis. This new drug effectively kills cancer cells in preclinical models and human cell cultures, offering a promising cancer treatment strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Development

Background:

  • The BCL-2 gene, identified in 1985 from the t(14;18) translocation in follicular lymphomas, plays a key role in preventing programmed cell death (apoptosis).
  • Dysregulation of BCL-2 contributes to cancer cell survival by inhibiting apoptosis.

Purpose of the Study:

  • To develop and validate a small-molecule antagonist with high affinity for BCL-2.
  • To assess the efficacy of this antagonist in eliminating cancer cells.

Main Methods:

  • Cloning of the BCL-2 gene.
  • Development of a small-molecule antagonist targeting BCL-2.
  • In vitro testing on primary human cancer cells.
  • In vivo testing using mouse xenograft models.

Main Results:

  • A high-affinity, mechanistically validated small-molecule antagonist of BCL-2 was successfully developed.
  • The antagonist demonstrated efficacy in killing cancer cells in both mouse xenograft models and in vitro human cancer cell cultures.
  • This achievement highlights a significant advancement in rational drug development over two decades.

Conclusions:

  • The developed small-molecule BCL-2 antagonist shows significant potential for cancer therapy.
  • Targeting antiapoptotic proteins like BCL-2 offers a promising strategy for selectively inducing cancer cell death.
  • Further investigation into BCL-2 antagonists could lead to novel cancer treatments.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...